Log in

NASDAQ:IDRA - Idera Pharmaceuticals Stock Price, Forecast & News

+0.03 (+1.82 %)
(As of 02/24/2020 09:13 AM ET)
Today's Range
Now: $1.68
50-Day Range
MA: $1.77
52-Week Range
Now: $1.68
Volume182,606 shs
Average Volume168,132 shs
Market Capitalization$48.50 million
P/E RatioN/A
Dividend YieldN/A
Idera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for oncology in the United States. It offers Tilsotolimod, a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, metastatic melanoma, squamous cell carcinoma, and colorectal cancer. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:IDRA



Sales & Book Value

Annual Sales$660,000.00
Book Value$2.35 per share


Net Income$-59,880,000.00


Market Cap$48.50 million
Next Earnings Date3/4/2020 (Estimated)

Receive IDRA News and Ratings via Email

Sign-up to receive the latest news and ratings for IDRA and its competitors with MarketBeat's FREE daily newsletter.

Idera Pharmaceuticals (NASDAQ:IDRA) Frequently Asked Questions

What is Idera Pharmaceuticals' stock symbol?

Idera Pharmaceuticals trades on the NASDAQ under the ticker symbol "IDRA."

When did Idera Pharmaceuticals' stock split? How did Idera Pharmaceuticals' stock split work?

Idera Pharmaceuticals shares reverse split before market open on Monday, July 30th 2018. The 1-8 reverse split was announced on Friday, July 27th 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 27th 2018. An investor that had 100 shares of Idera Pharmaceuticals stock prior to the reverse split would have 13 shares after the split.

How were Idera Pharmaceuticals' earnings last quarter?

Idera Pharmaceuticals Inc (NASDAQ:IDRA) posted its quarterly earnings results on Wednesday, November, 6th. The biotechnology company reported ($0.39) EPS for the quarter, topping analysts' consensus estimates of ($0.47) by $0.08. View Idera Pharmaceuticals' Earnings History.

When is Idera Pharmaceuticals' next earnings date?

Idera Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for Idera Pharmaceuticals.

What price target have analysts set for IDRA?

3 equities research analysts have issued 1-year price objectives for Idera Pharmaceuticals' stock. Their forecasts range from $7.00 to $14.00. On average, they expect Idera Pharmaceuticals' share price to reach $9.33 in the next twelve months. This suggests a possible upside of 455.6% from the stock's current price. View Analyst Price Targets for Idera Pharmaceuticals.

What is the consensus analysts' recommendation for Idera Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Idera Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Idera Pharmaceuticals.

Has Idera Pharmaceuticals been receiving favorable news coverage?

Media headlines about IDRA stock have been trending negative this week, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Idera Pharmaceuticals earned a coverage optimism score of -2.1 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an effect on the stock's share price in the next several days. View News Stories for Idera Pharmaceuticals.

Are investors shorting Idera Pharmaceuticals?

Idera Pharmaceuticals saw a drop in short interest in the month of January. As of January 31st, there was short interest totalling 370,700 shares, a drop of 21.8% from the January 15th total of 474,100 shares. Based on an average daily trading volume, of 213,200 shares, the days-to-cover ratio is currently 1.7 days. Currently, 1.5% of the company's shares are sold short. View Idera Pharmaceuticals' Current Options Chain.

Who are some of Idera Pharmaceuticals' key competitors?

What other stocks do shareholders of Idera Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Idera Pharmaceuticals investors own include Oasis Petroleum (OAS), BioCryst Pharmaceuticals (BCRX), Novavax (NVAX), Anavex Life Sciences (AVXL), Proteostasis Therapeutics (PTI), Verastem (VSTM), Inovio Pharmaceuticals (INO), Geron (GERN), TrovaGene (TROV) and Celldex Therapeutics (CLDX).

Who are Idera Pharmaceuticals' key executives?

Idera Pharmaceuticals' management team includes the folowing people:
  • Mr. Vincent J. Milano, Pres, CEO & Director (Age 55)
  • Mr. John J. Kirby, VP of Fin., Principal Financial Officer & Principal Accounting Officer (Age 47)
  • Dr. Jonathan Yingling, Sr. VP of Early Devel. & Chief Scientific Officer (Age 50)
  • Mr. Robert Clayton Fletcher, Sr. VP of Bus. Devel. & Strategic Planning (Age 56)
  • Dr. Joanna C. Horobin, Sr. VP & Chief Medical Officer (Age 64)

Who are Idera Pharmaceuticals' major shareholders?

Idera Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (1.89%), Oxford Asset Management LLP (0.55%), Jacobs Levy Equity Management Inc. (0.54%), Acadian Asset Management LLC (0.45%), DCF Advisers LLC (0.18%) and Citigroup Inc. (0.14%). Company insiders that own Idera Pharmaceuticals stock include Bryant David Lim, Carol Schafer, Invest Corp Pillar, James A Geraghty, Joanna Horobin, John J Kirby, Jonathan Michael Yingling, Robert C Fletcher and Vincent Milano. View Institutional Ownership Trends for Idera Pharmaceuticals.

Which major investors are selling Idera Pharmaceuticals stock?

IDRA stock was sold by a variety of institutional investors in the last quarter, including Oxford Asset Management LLP, Bank of New York Mellon Corp, Acadian Asset Management LLC, Hollencrest Capital Management and Citigroup Inc.. Company insiders that have sold Idera Pharmaceuticals company stock in the last year include Bryant David Lim, Invest Corp Pillar, John J Kirby, Jonathan Michael Yingling, Robert C Fletcher and Vincent Milano. View Insider Buying and Selling for Idera Pharmaceuticals.

Which major investors are buying Idera Pharmaceuticals stock?

IDRA stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Jacobs Levy Equity Management Inc., DCF Advisers LLC, Virtu Financial LLC and Wedbush Securities Inc.. Company insiders that have bought Idera Pharmaceuticals stock in the last two years include Bryant David Lim, Carol Schafer, James A Geraghty, Joanna Horobin and Vincent Milano. View Insider Buying and Selling for Idera Pharmaceuticals.

How do I buy shares of Idera Pharmaceuticals?

Shares of IDRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Idera Pharmaceuticals' stock price today?

One share of IDRA stock can currently be purchased for approximately $1.68.

How big of a company is Idera Pharmaceuticals?

Idera Pharmaceuticals has a market capitalization of $48.50 million and generates $660,000.00 in revenue each year. The biotechnology company earns $-59,880,000.00 in net income (profit) each year or ($2.28) on an earnings per share basis. Idera Pharmaceuticals employs 36 workers across the globe.View Additional Information About Idera Pharmaceuticals.

What is Idera Pharmaceuticals' official website?

The official website for Idera Pharmaceuticals is http://www.iderapharma.com/.

How can I contact Idera Pharmaceuticals?

Idera Pharmaceuticals' mailing address is 505 EAGLEVIEW BLVD. SUITE 212, EXTON PA, 19341. The biotechnology company can be reached via phone at 484-348-1600 or via email at [email protected]

MarketBeat Community Rating for Idera Pharmaceuticals (NASDAQ IDRA)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  365 (Vote Outperform)
Underperform Votes:  276 (Vote Underperform)
Total Votes:  641
MarketBeat's community ratings are surveys of what our community members think about Idera Pharmaceuticals and other stocks. Vote "Outperform" if you believe IDRA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IDRA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel